Biotronik’s Dreams scaffold receives first patient implant

Biotronik has announced that its bioabsorbable magnesium scaffold Dreams has been successfully implanted in a patient for the first time.

Professor Dr Michael Haude from the Lukaskrankenhaus in Neuss, Germany implanted the device as part of the new Biosolve-II clinical study, which aims to further demonstrate the safety and efficacy of the device following the success of the earlier Biosolve-I study.

Approximately 120 patients are expected to be enrolled in the trial – with follow-up investigations performed at predetermined intervals over a 36-month period – and the primary endpoint is in-segment late lumen loss.

Professor Haude praised the ease of deliverability and vessel adaptability of the device, which will be submitted for regulatory approval following a successful outcome to this trial.

Dr Daniel Buehler, president of vascular intervention at Biotronik, said: "With the promising clinical data of our first generation in the Biosolve-I study and the preclinical data of this new generation, I am confident that this groundbreaking treatment will prove its efficacy."

This comes after the firm launched its new Idova 7 series of implantable cardioverter-defibrillators and cardiac resynchronisation therapy defibrillators earlier this month.